These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 3167234)
21. Tumor markers in mammary carcinoma. An evaluation of carcinoembryonic antigen, placental alkaline phosphatase, pseudouridine and CA-50. Rasmuson T; Björk GR; Damber L; Jacobsson L; Jeppsson A; Stigbrand T; Westman G Acta Oncol; 1987; 26(4):261-7. PubMed ID: 3479987 [TBL] [Abstract][Full Text] [Related]
22. Follow-up of metastatic breast cancer patients with a mucin-like carcinoma-associated antigen: comparison to CA 15.3 and carcinoembryonic antigen. Bieglmayer C; Szepesi T; Neunteufel W Cancer Lett; 1988 Nov; 42(3):199-206. PubMed ID: 2461250 [TBL] [Abstract][Full Text] [Related]
23. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Ward U; Primrose JN; Finan PJ; Perren TJ; Selby P; Purves DA; Cooper EH Br J Cancer; 1993 May; 67(5):1132-5. PubMed ID: 8494712 [TBL] [Abstract][Full Text] [Related]
24. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Safi F; Kohler I; Röttinger E; Beger H Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278 [TBL] [Abstract][Full Text] [Related]
25. [Sensitivity and specificity of CEA, Ca 15-3 and MCA levels in visceral breast carcinoma metastasis]. Delbrück H; Hagen-Aukamp C; Braun G Strahlenther Onkol; 1990 Jul; 166(7):457-9. PubMed ID: 2200152 [TBL] [Abstract][Full Text] [Related]
26. CA-15.3, TPA and MCA as markers for breast cancer. Barak M; Steiner M; Finkel B; Abrahamson J; Antal S; Gruener N Eur J Cancer; 1990; 26(5):577-80. PubMed ID: 2144745 [TBL] [Abstract][Full Text] [Related]
27. Serum markers for breast cancer. Stenman UH; Heikkinen R Scand J Clin Lab Invest Suppl; 1991; 206():52-9. PubMed ID: 1947760 [TBL] [Abstract][Full Text] [Related]
28. The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer. Hall NR; Finan PJ; Stephenson BM; Purves DA; Cooper EH Br J Cancer; 1994 Sep; 70(3):549-53. PubMed ID: 8080745 [TBL] [Abstract][Full Text] [Related]
29. Carcinoembryonic antigen and breast carcinoma antigen (CA 15.3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast. Omar YT; Behbehani AE; al-Naqeeb N; Motawy MM; Folldi MO; Awwad AH; Nasralla MY; Szymendera JJ Int J Biol Markers; 1988; 3(3):165-71. PubMed ID: 3230336 [TBL] [Abstract][Full Text] [Related]
30. Expression of monoclonal antibody-defined tumor markers in four carcinomas. Wu JT Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833 [TBL] [Abstract][Full Text] [Related]
31. Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Munck-Wikland E; Kuylenstierna R; Wahren B; Lindholm J; Haglund S Cancer; 1988 Dec; 62(11):2281-6. PubMed ID: 3179942 [TBL] [Abstract][Full Text] [Related]
32. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of radioimmunoscintigraphy using a I-131 anti CEA and CA 19-9 monoclonal antibodies cocktail (IMACIS-1)]. Takahashi T; Tsujino D; Kato Y; Wada Y; Someya K; Itagaki K; Imanishi Y; Ishikawa T; Sakaki T; Sasaki Y Gan No Rinsho; 1989 Jun; 35(7):828-33. PubMed ID: 2739074 [TBL] [Abstract][Full Text] [Related]
34. [The value of tumor markers in colorectal cancer]. Peters KM; Grundmann R Leber Magen Darm; 1989 Jan; 19(1):18-25. PubMed ID: 2927234 [TBL] [Abstract][Full Text] [Related]
35. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours. Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097 [TBL] [Abstract][Full Text] [Related]
36. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients]. Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168 [TBL] [Abstract][Full Text] [Related]
37. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Colomer R; Ruibal A; Salvador L Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682 [TBL] [Abstract][Full Text] [Related]
38. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis. Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Kiviranta A; Hallman K; Holm L; Weiner E; Tamsen L Gynecol Oncol; 1990 Oct; 39(1):16-25. PubMed ID: 2227569 [TBL] [Abstract][Full Text] [Related]
39. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma. Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396 [TBL] [Abstract][Full Text] [Related]
40. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma. Silver HK; Archibald BL; Ragaz J; Coldman AJ Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]